MR Microimaging of amyloid plaques in Alzheimer's disease transgenic mice

Thomas M. Wengenack, Clifford R. Jack, Michael Garwood, Joseph F. Poduslo

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


Introduction: Alzheimer's disease (AD) is the most prevalent neurological condition affecting industrialized nations and will rapidly become a healthcare crisis as the population ages. Currently, the post-mortem histological observation of amyloid plaques and neurofibrillary tangles is the only definitive diagnosis available for AD. A pre-mortem biological or physiological marker specific for AD used in conjunction with current neurological and memory testing could add a great deal of confidence to the diagnosis of AD and potentially allow therapeutic intervention much earlier in the disease process. Discussion and conclusion: Our group has developed MRI techniques to detect individual amyloid plaques in AD transgenic mouse brain in vivo. We are also developing contrast-enhancing agents to increase the specificity of detection of amyloid plaques. Such in vivo imaging of amyloid plaques will also allow the evaluation of anti-amyloid therapies being developed by the pharmaceutical industry in pre-clinical trials of AD transgenic mice. This short review briefly discusses our progress in these areas.

Original languageEnglish (US)
Pages (from-to)S82-S88
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue numberSUPPL. 1
StatePublished - Mar 2008


  • Alzheimer's disease
  • Amyloid-β
  • Magnetic resonance imaging
  • Plaque
  • Transgenic mouse

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'MR Microimaging of amyloid plaques in Alzheimer's disease transgenic mice'. Together they form a unique fingerprint.

Cite this